| |JUNE 20248Akums Drugs & Pharmaceuticals Ltd declared the launch of Rabeprazole + Levosulpiride SR capsules. This new formulation, which was approved by the Drug Controller General of India (DCGI), aims to provide patients with better relief from disorders of the gastrointestinal tract (GIT) disorders.GERD, or gastro-oesophageal reflux infection, is a crippling condition described by the reflux of stomach contents into the throat, prompting inconvenient side effects and potential complications. With GERD often dubbed as chronic acid reflux, has a negative impact on quality of life and increases the risk of serious health problems like stomach and esophageal cancer.Rabeprazole sodium, a potent antisecretory compound, targets the H+ and K+ ATPase on the surface of gastric parietal cells to selectively inhibit gastric acid secretion. It has been shown to be effective in treating GERD as well as gastric and duodenal ulcers. In addition to rabeprazole, the levo-enantiomer of sulpiride, levosulpiride, has significant antiemetic and central antidopaminergic activity. It is useful in gastroenterology because its peripheral anti-dopaminergic action regulates the motor activity of the upper digestive tract.Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd, commented, "We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and booste patients' overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience." POAKUMS LAUNCHES RABEPRAZOLE & LEVOSULPIRIDE SR CAPSULES FOR GIT DISORDERSESSENTIAL PHARMA INK PACT WITH AGC BIOLOGICS TO TREAT HIGH-RISK NEUROBLASTOMA TOP STORIESEssential Pharma, an international specialty pharmaceutical group dedicated to guaranteeing patients' long-term availability of low volume, clinically differentiated, niche pharmaceutical products across key therapeutic fields, declared that its rare disease business has signed a strategic agreement with AGC Biologics. AGC Biologics, a major worldwide biopharmaceutical contract development and manufacturing organization (CDMO), will manufacture Hu1418K322A (Hu14.18), a humanized monoclonal antibody being developed for Essential Pharma to treat high-risk neuroblastoma (HRNB). According to the agreement, AGC Biologics will help with process development, scale-up, and manufacturing as Essential Pharma prepares to begin clinical activities and continued regulatory agency engagements in the coming months.Simon Ball, Vice President of the rare disease business at Essential Pharma, commented: "This partnership is a tremendous milestone in the development of Hu14.18 and its path to commercialization. The prospect of building an inventory of Hu14.18 is very exciting. Ahead of us is a period of intense regulatory agency interaction, which will take place alongside late-stage clinical development, and we are a step closer to providing this high-potential antibody to a patient group that is desperately in need of more optimal treatments and better outcomes.""AGC Biologics is a global leader in contract antibody development and manufacturing," stated Emma Johnson, CEO of Essential Pharma. "This partnership will help us to accelerate the late-stage development of Hu14.18, which shows therapeutic promise for high-risk neuroblastoma patients, the majority of whom are young children. We look forward to working closely with AGC to deliver this potentially transformative therapy in an area of significant unmet need." POAkums Launches Rabeprazole and Levosulpiride SR Capsules For GIT Disorders
< Page 7 | Page 9 >